Medicines labeled for the same conditions
Alternatives to bempedoic acid and ezetimibe
16 other medicines are given the same way (oral) and in the same FDA class as bempedoic acid and ezetimibe or labeled mainly for the same use (high cholesterol); the others include 7 HMG-CoA reductase inhibitors, 3 peroxisome proliferator receptor alpha agonists and 3 bile acid sequestrants (FDA labels read October 8, 2026).
Which medicines are labeled for the same conditions as bempedoic acid and ezetimibe?
High cholesterol lists all 25 medicines labeled for it, by any route. Each row shows the conditions both labels name. They are listed as public records, not as substitutes: whether one can replace another depends on the person and is a prescriber's decision.
| Medicine and FDA class | Shared indication | Generic labelers (oral) | Pharmacy cost | Boxed warning | Shortage |
|---|---|---|---|---|---|
| Bempedoic acid and ezetimibeadenosine triphosphate-citrate lyase inhibitor | this medicine | none listed | $13.80 per tablet 180-10 mg tablet | No | No current entry |
| AtorvastatinHMG-CoA reductase inhibitor | Heart attack and coronary artery disease, High cholesterol | 61 labelers | $0.0228 per tablet 10 mg tablet | No | No current entry |
| RosuvastatinHMG-CoA reductase inhibitor | Heart attack and coronary artery disease, High cholesterol | 46 labelers | $0.0692 per tablet 40 mg tablet | No | No current entry |
| Fenofibrateperoxisome proliferator receptor alpha agonist | High cholesterol | 54 labelers | $0.103 per tablet 160 mg tablet | No | No current entry |
| PravastatinHMG-CoA reductase inhibitor | Heart attack and coronary artery disease, High cholesterol | 37 labelers | $0.058 per tablet 20 mg tablet | No | No current entry |
| SimvastatinHMG-CoA reductase inhibitor | Heart attack and coronary artery disease, High cholesterol | 27 labelers | $0.0321 per tablet 20 mg tablet | No | No current entry |
| LovastatinHMG-CoA reductase inhibitor | Heart attack and coronary artery disease, High cholesterol | 19 labelers | $0.0436 per tablet 20 mg tablet | No | No current entry |
| Gemfibrozilperoxisome proliferator receptor alpha agonist | Heart attack and coronary artery disease, High cholesterol | 27 labelers | $0.104 per tablet 600 mg tablet | Yes | A presentation being discontinued |
| PitavastatinHMG-CoA reductase inhibitor | High cholesterol | 12 labelers | $0.954 per tablet 2 mg tablet | No | No current entry |
| Cholestyraminebile acid sequestrant | High cholesterol | 15 labelers | $0.834 per packet Cholestyramine packet | No | No current entry |
| Colesevelambile acid sequestrant | High cholesterol | 15 labelers | $0.262 per tablet 625 mg tablet | No | No current entry |
| Niacinnicotinic acid | Heart attack and coronary artery disease, High cholesterol | 13 labelers | $0.193 per tablet 500 mg tablet | No | No current entry |
| Colestipolbile acid sequestrant | High cholesterol | 8 labelers | $0.658 per tablet 1 g tablet | No | No current entry |
| Fenofibric acidperoxisome proliferator receptor alpha agonist | High cholesterol | 7 labelers | $0.286 per capsule 135 mg capsule | No | No current entry |
| FluvastatinHMG-CoA reductase inhibitor | High cholesterol | 4 labelers | $2.88 per tablet 80 mg tablet | No | A presentation being discontinued |
| Lomitapidemicrosomal triglyceride transfer protein inhibitor | High cholesterol | none listed | n/a | Yes | No current entry |
| Enlicitide | High cholesterol | none listed | n/a | No | No current entry |
Source: FDA drug labels (indications) via openFDA; FDA NDC Directory; CMS NADAC of October 7, 2026; FDA Drug Shortage Database (FDA files October 8, 2026)
What do pharmacies pay for each?
The headline NADAC price per unit of each medicine's most widely listed form; strengths differ, so compare like with like on each record.
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What next?
- Bempedoic acid and ezetimibe: the full record
- label, generics, price, shortages, recalls